TumorManager™ Software

About Biopticon

Founded in 2003, Biopticon specializes in creating advanced tools for preclinical cancer research, focusing on improving the accuracy and efficiency of tumor measurement and study management. Their flagship Tumor Management System, comprising the TumorImager-2 scanner and TumorManager software, is designed to replace traditional, less reliable caliper-based methods. The company collaborates with pharmaceutical partners like Bristol-Myers Squibb and leverages academic expertise from institutions such as Princeton University. Biopticon's mission is to provide researchers with superior data quality and workflow management in oncology drug development.

Therapeutic Areas